The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, as compared with docetaxel in this patient population. METHODS: We randomly assigned 272 patients to receive nivolumab, at a dose of 3 mg per kilogram of body weight every 2 weeks, or docetaxel, at a dose of 75 mg per square meter of body-surface area every 3 weeks. The primary end point was overall survival. RESULTS: The median overall survival was 9.2 months (95% confidence interval [CI], 7.3 to 13.3) with nivolumab versus 6.0 months (95% CI, 5.1 to 7.3) with docetaxel. The risk of death was 41% lower with nivolumab than with docetaxel (hazard ratio, 0.59; 95% CI, 0.44 to 0.79; P<0.001). At 1 year, the overall survival rate was 42% (95% CI, 34 to 50) with nivolumab versus 24% (95% CI, 17 to 31) with docetaxel. The response rate was 20% with nivolumab versus 9% with docetaxel (P=0.008). The median progression-free survival was 3.5 months with nivolumab versus 2.8 months with docetaxel (hazard ratio for death or disease progression, 0.62; 95% CI, 0.47 to 0.81; P<0.001). The expression of the PD-1 ligand (PD-L1) was neither prognostic nor predictive of benefit. Treatment-related adverse events of grade 3 or 4 were reported in 7% of the patients in the nivolumab group as compared with 55% of those in the docetaxel group. CONCLUSIONS: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level. (Funded by Bristol-Myers Squibb; CheckMate 017 ClinicalTrials.gov number, NCT01642004.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nivolumab has significantly improved outcomes in patients with metastatic non-small cell lung cancer (NSCLC); however, reliable prognostic biomarkers remain an unmet need.”
From SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“The development of immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 interaction has transformed the therapeutic landscape of patients with advanced non-small cell lung cancer (NSCLC) [1][2][3][4][5][6] .”
From Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) · cites this paper as [2]
In the citing paper
“Landmark trials performed on previously treated patients with advanced NSCLC demonstrated superior overall survival (OS) with PD-1/PD-L1 blockade compared to standard chemotherapy [1][2][3] .”
From Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) · cites this paper as [2]
In the citing paper
“Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [72]
In the citing paper
“At the data cut-off, median OS was 9.2 months (95% CI: 7.3-13.3months) on nivolumab compared with 6.0 months (95% CI: 5.1-7.3months) on docetaxel, with a 41% reduction in the risk of death in the nivolumab arm (HR 0.59, 95% CI: 0.44-0.49;P < 0.001).”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“The expression of PD-L1 was neither prognostic nor predictive of clinical benefit in a retrospective analysis using various cut points in this study.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“A phase III trial (CheckMate 017) in patients previously treated for SCC compared 3 mg/kg of nivolumab given every 2 weeks with docetaxel, showing an improvement of 3.2 months [97,98]”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“In the phase III trial, nivolumab was better tolerated than docetaxel, with 85% of nivolumab patients receiving at least 90% of their planned dose intensity, compared with 69% of docetaxel patients, together with a treatment discontinuation rate of 10% versus 3% of the patients treated with nivolumab and docetaxel, respectively.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“The primary end point was overall response rate, which occurred in 17 (14.5%) of 117 patients (95% CI 8.7 to 22.2).”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
In the citing paper
“Median time to response was 3.3 months; median duration of response had not been reached at the time of publication.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
In the citing paper
“Adverse effects included dyspnea, fatigue, pneumonitis, diarrhea, musculoskeletal pain, and severe immune-mediated adverse effects98,99; 59% of patients experienced serious adverse events.100”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Self-citationHanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Flagged first, then by citations
Research works printed but not linked: 1
- Soria JC, 2013, Eur J Cancer, 49
Cited by
Sorted by citations
Items 701–800 of 1,048
Personalized therapy for lung cancer: striking a moving target
Pakkala, S., & Ramalingam, S. S. (2018) · JCI Insight · doi:10.1172/jci.insight.120858 · Cited by 154
Arrieta, O. G., Barrón, F., Ramírez-Tirado, L. A., Zatarain-Barrón, Z. L., Cardona, A. F., Díaz-García, D. A., Ramos, M. Y., Mota-Vega, B., Carmona, A., Álvarez, M. P. P., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0409 · Cited by 154
Ricciuti, B., Recondo, G., Spurr, L. F., Li, Y. Y., Lamberti, G., Venkatraman, D., Umeton, R., Cherniack, A. D., Nishino, M., Sholl, L. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3529 · Cited by 154
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
Collins, M., Michot, J., Danlos, F. X., Mussini, C., Soularue, É., Mateus, C., Loirat, D., Buisson, A., Rosa, I., Lambotte, O., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx403 · Cited by 153
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
Crinò, L., Bronte, G., Bidoli, P., Cravero, P., Minenza, E., Cortesi, E., Garassino, M. C., Proto, C., Cappuzzo, F., Grossi, F., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.025 · Cited by 153
Self-citationAjona, D., Ortiz‐Espinosa, S., Lozano, T., Expósito, F., Calvo, A., Valencia, K., Redrado, M., Remírez, A., Lecanda, F., Alignani, D., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0007-9 · Cited by 154
Planchard, D., Reinmuth, N., Орлов, С. В., Fischer, J. R., Sugawara, S., Mańdziuk, S., Márquez-Medina, D., Novello, S., Takeda, Y., Soo, R. A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.006 · Cited by 153
Morgan, M. A., Büning, H., Sauer, M. G., & Schambach, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01965 · Cited by 153
Zhou, J., Wu, Z., Hu, J., Yang, D., Chen, X., Wang, Q., Liu, J., Dou, M., Peng, W., Wu, Y., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc1204 · Cited by 153
An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer
Karasaki, T., Nagayama, K., Kuwano, H., Nitadori, J., Sato, M., Anraku, M., Hosoi, A., Matsushita, H., Morishita, Y., Kashiwabara, K., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.005 · Cited by 152
Yamaguchi, T., Shimizu, J., Hasegawa, T., Horio, Y., Inaba, Y., Yatabe, Y., & Hida, T. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.001 · Cited by 152
Janjigian, Y. Y., Cutsem, E. V., Muro, K., Wainberg, Z. A., Al‐Batran, S., Hyung, W. J., Molena, D., Marcovitz, M., Ruscica, D., Robbins, S. H., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0093 · Cited by 152
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
Zhang, M., Liu, J., & Xia, Q. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00442-x · Cited by 153
Targeting the interleukin-17 immune axis for cancer immunotherapy
Vitiello, G. A., & Miller, G. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190456 · Cited by 151
Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis
Fujita, K., Terashima, T., & Mio, T. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.07.006 · Cited by 151
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
Riaz, N., Havel, J. J., Kendall, S. M., Makarov, V., Walsh, L. A., Desrichard, A., Weinhold, N., & Chan, T. A.-T. (2016) · Nature Genetics · doi:10.1038/ng.3677 · Cited by 151
Paggio, J. C. D., Sullivan, R. J., Schrag, D., Hopman, W. M., Biju Azariah, M., Pramesh, C. S., Tannock, I. F., & Booth, C. M. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30415-1 · Cited by 151
Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer
Gao, Y., Shi, S., Ma, W., Chen, J., Cai, Y., Ge, L., Li, L., Wu, J., & Tian, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.03.045 · Cited by 151
Rizzo, A., Santoni, M., Mollica, V., Logullo, F. O., Rosellini, M., Marchetti, A., Faloppi, L., Battelli, N., & Massari, F. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029405 · Cited by 151
Santoni, M., Rizzo, A., Kucharz, J., Mollica, V., Rosellini, M., Marchetti, A., Tassinari, E., Monteiro, F. S. M., Soares, A., Molina‐Cerrillo, J., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03349-4 · Cited by 151
Targeted Therapies for Ovarian Cancer
Grunewald, T., & Ledermann, J. A. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.12.001 · Cited by 150
Sun, X., Roudi, R., Dai, T., Chen, S., Fan, B., Li, H., Zhou, Y., Zhou, M., Zhu, B., Yin, C., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5701-6 · Cited by 150
Georgiadis, A. P., Durham, J. N., Keefer, L. A., Bartlett, B. R., Zielonka, M., Murphy, D. M., White, J. R., Lu, S., Verner, E. L., Ruan, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1372 · Cited by 150
Advances and prospects of biomarkers for immune checkpoint inhibitors
Yamaguchi, H., Hsu, J.-M., Sun, L., Wang, S., & Hung, M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101621 · Cited by 152
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Festino, L., Botti, G., Lorigan, P. C., Masucci, G. V., Hipp, J., Horak, C. E., Melero, I., & Ascierto, P. A. (2016) · Drugs · doi:10.1007/s40265-016-0588-x · Cited by 149
Li, Y., Li, F., Jiang, F., Lv, X., Zhang, R., Lü, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071151 · Cited by 149
Briere, D. M., Sudhakar, N., Woods, D. M., Hallin, J. F., Engstrom, L. D., Aranda, R., Chiang, H., Sodré, A. L., Olson, P., Weber, J. S., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2091-y · Cited by 149
Dantoing, E., Piton, N., Salaün, M., Thiberville, L., & Guisier, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126288 · Cited by 150
Biomarkers for Immunotherapy: Current Developments and Challenges
Spencer, K. R., Wang, J., Silk, A. W., Ganesan, S., Kaufman, H. L., & Mehnert, J. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_160766 · Cited by 148
Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation
Dieterich, L. C., Ikenberg, K., Cetintas, T., Kapaklikaya, K., Hutmacher, C., & Detmar, M. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00066 · Cited by 148
Extracellular nucleosides and nucleotides as immunomodulators
Kepp, O., Loos, F., Liu, P., & Kroemer, G. (2017) · Immunological Reviews · doi:10.1111/imr.12571 · Cited by 149
Precision immunoprofiling by image analysis and artificial intelligence
Koelzer, V. H., Sirinukunwattana, K., Rittscher, J., & Mertz, K. D. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2485-z · Cited by 148
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
Akamatsu, H., Ninomiya, K., Kenmotsu, H., Morise, M., Daga, H., Goto, Y., Kozuki, T., Miura, S., Sasaki, T., Tamiya, A., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01431-z · Cited by 149
Chen, S., Zhang, Z., Zheng, X., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Cui, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.562315 · Cited by 156
Abdel-Rahman, O. M., Elhalawani, H. M., & Fouad, M. (2016) · Future Oncology · doi:10.2217/fon.15.222 · Cited by 147
Anti–PD-1 Inhibitor–Related Pneumonitis in Non–Small Cell Lung Cancer
Nishino, M., Chambers, E. S., Chong, C. R., Ramaiya, N. H., Gray, S. W., Marcoux, J. P., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0267 · Cited by 147
Doi, T., Ishikawa, T., Okayama, T., Oka, K., Mizushima, K., Yasuda, T., Sakamoto, N., Katada, K., Kamada, K., Uchiyama, K., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5399 · Cited by 147
Wang, W., Lie, P., Guo, M., & He, J. (2017) · International Journal of Cancer · doi:10.1002/ijc.30678 · Cited by 147
Fujimoto, D., Yoshioka, H., Kataoka, Y., Morimoto, T., Kim, Y. H., Tomii, K., Ishida, T., Hirabayashi, M., Hara, S., Ishitoko, M., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.02.017 · Cited by 147
Combining chemotherapy with PD-1 blockade in NSCLC
Mathew, M., Enzler, T., Shu, C. A., & Rizvi, N. A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.003 · Cited by 147
The clinical promise of immunotherapy in triple-negative breast cancer
Vikas, P., Borcherding, N. C., & Zhang, W. (2018) · Cancer Management and Research · doi:10.2147/cmar.s185176 · Cited by 147
Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
Wang, Q., & Wu, X. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.03.015 · Cited by 146
Chemokines and cancer: new immune checkpoints for cancer therapy
Karin, N. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.004 · Cited by 146
Owen, D. H., Wei, L., Bertino, E. M., Edd, T., Villalona-Calero, M. A., He, K., Shields, P. G., Carbone, D. P., & Otterson, G. A. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.08.008 · Cited by 146
Reynolds, K. L., & Guidon, A. C. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0359 · Cited by 146
M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer
Cao, L., Che, X., Qiu, X.-S., Li, Z., Yang, B., Wang, S., Hou, K., Fan, Y., Qu, X., & Liu, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s199832 · Cited by 146
Vieira, T., Antoine, M., Hamard, C., Fallet, V., Duruisseaux, M., Rabbe, N., Rodenas, A., Cadranel, J. L., & Wislez, M. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.013 · Cited by 145
Lopci, E., Toschi, L., Grizzi, F., Rahal, D., Olivari, L., Castino, G. F., Marchetti, S., Cortese, N., Qehajaj, D., Pistillo, D., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3425-2 · Cited by 145
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon
Rolfo, C. D., Caglevic, C., Santarpía, M., Araújo, A., Giovannetti, E., Gallardo, C. D., Pauwels, P., & Mahave, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53156-4_5 · Cited by 145
Kordbacheh, T., Honeychurch, J., Blackhall, F. H., Finn, C. F., & Illidge, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx790 · Cited by 145
Nixon, N. A., Blais, N., Ernst, S., Kollmannsberger, C., Bebb, G. D., Butler, M. O., Smylie, M., & Verma, S. (2018) · Current Oncology · doi:10.3747/co.25.3840 · Cited by 145
Immunotherapy for Advanced Non–Small Cell Lung Cancer: A Decade of Progress
Shields, M. D., Marin-Acevedo, J. A., & Pellini, B. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321483 · Cited by 145
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.002 · Cited by 144
Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?
Hilmi, M., Jouinot, A., Burns, R. G., Pigneur, F., Mounier, R., Gondin, J., Neuzillet, C., & Goldwasser, F. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.003 · Cited by 145
Tunali, I., Gray, J. E., Qi, J., Abdalah, M. A., Jeong, D. K., Güveniş, A., Gillies, R. J., & Schabath, M. B. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.010 · Cited by 144
Combination therapy with PD-1 or PD-L1 inhibitors for cancer
Hayashi, H., & Nakagawa, K. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01548-1 · Cited by 144
An update on the immune landscape in lung and head and neck cancers
Carlisle, J. W., Steuer, C. E., Owonikoko, T. K., & Saba, N. F. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21630 · Cited by 144
Besse, B., Tostivint, E. P., Park, K., Hartl, S., Forde, P. M., Hochmair, M. J., Awad, M. M., Thomas, M., Goss, G. D., Wheatley‐Price, P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02808-y · Cited by 144
Wang, J., Wang, B., Chu, H., & Yao, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106399 · Cited by 143
Drug discovery in advanced prostate cancer: translating biology into therapy
Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 143
PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells
Wei, X., Lai, Y., Li, J., Qin, L., Xu, Y., Zhao, R., Li, B., Lin, S., Wang, S., Wu, Q., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1284722 · Cited by 143
Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer
Zhao, J., Schlößer, H., Wang, Z., Qin, J., Li, J., Popp, F., Popp, M. C., Alakus, H., Chon, S., Hansen, H. P., et al. (2019) · Cancers · doi:10.3390/cancers11060874 · Cited by 143
Masuda, K., Shoji, H., Nagashima, K., Yamamoto, S., Ishikawa, M., Imazeki, H., Aoki, M., Miyamoto, T., Hirano, H., Honma, Y., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6150-y · Cited by 143
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non−Small Cell Lung Cancer
Rakaee, M., Tafavvoghi, M., Ricciuti, B., Alessi, J. V., Cortellini, A., Citarella, F., Nibid, L., Perrone, G., Adib, E., Fulgenzi, C. A. M., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.5356 · Cited by 143
Zappasodi, R., Budhu, S., Hellmann, M. D., Postow, M. A., Senbabaoglu, Y., Manne, S., Gasmi, B., Liu, C., Zhong, H., Li, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.009 · Cited by 142
Lee, K. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.001 · Cited by 142
Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment
Ajona, D., Ortiz‐Espinosa, S., & Pı́o, R. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.11.023 · Cited by 142
Núñez, N. G., Berner, F., Friebel, E., Unger, S., Wyss, N., Gómez, J. M. M., Purde, M.-T., Niederer, R., Porsch, M., Lichtensteiger, C., et al. (2023) · Med · doi:10.1016/j.medj.2022.12.007 · Cited by 142
Rakaee, M., Adib, E., Ricciuti, B., Sholl, L. M., Shi, W., Alessi, J. V., Cortellini, A., Fulgenzi, C. A. M., Viola, P., Pinato, D. J., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.4933 · Cited by 141
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
Swart, M., Verbrugge, I., & Beltman, J. B. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00233 · Cited by 141
Ma, K., Lu, Y., Jiang, S., Tang, J., Li, X., & Zhang, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01430 · Cited by 142
Wu, Y., Xu, J., Du, C., Wu, Y., Xia, D., Lv, W., & Hu, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01161 · Cited by 143
Genome-wide methylation patterns predict clinical benefit of immunotherapy in lung cancer
Kim, J. Y., Choi, J. K., & Jung, H. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00907-4 · Cited by 141
Rizzo, A., Mollica, V., Tateo, V., Tassinari, E., Marchetti, A., Rosellini, M., Luca, R. D., Santoni, M., & Massari, F. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03366-x · Cited by 141
Ricciuti, B., Lamberti, G., Puchala, S. R., Mahadevan, N. R., Lin, J., Alessi, J. V., Chowdhury, A., Li, Y. Y., Wang, X., Spurr, L. F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.00580 · Cited by 141
Mark, N. M., Kargl, J., Busch, S., Yang, G. H. Y., Metz, H. E., Zhang, H., Hubbard, J. J., Pipavath, S. N. J., Madtes, D. K., & Houghton, A. M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201704-0795oc · Cited by 140
Thompson, J. C., Hwang, W., Davis, C. W., Deshpande, C. G., Jeffries, S., Rajpurohit, Y. R., Krishna, V., Smirnov, D. S., Verona, R. I., Lorenzi, M. V., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.012 · Cited by 140
Ocular and orbital side-effects of checkpoint inhibitors: a review article
Antoun, J., Titah, C., & Cochereau, I. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000296 · Cited by 139
The Biology of Aging and Cancer
Zhang, X., Meng, X., Chen, Y., Leng, S. X., & Zhang, H. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000270 · Cited by 139
Kanai, O., Kim, Y. H., Demura, Y., Kanai, M., Ito, T., Fujita, K., Yoshida, H., Akai, M., Mio, T., & Hirai, T. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12759 · Cited by 139
Seban, R., Mezquita, L., Berenbaum, A., Dercle, L., Botticella, A., Pechoux, C. L., Caramella, C., Deutsch, É., Grimaldi, S., Adam, J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04615-x · Cited by 139
Endocrinological side-effects of immune checkpoint inhibitors
Torino, F., Corsello, S. M., & Salvatori, R. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000293 · Cited by 138
Colli, L. M., Machiela, M. J., Myers, T. A., Jessop, L., Yu, K. F., & Chanock, S. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0170 · Cited by 138
Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors
Bott, M. J., Cools‐Lartigue, J., Tan, K. S., Dycoco, J., Bains, M. S., Downey, R. J., Huang, J. G., Isbell, J. M., Molena, D., Park, B. J., et al. (2018) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2018.02.030 · Cited by 138
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124325 · Cited by 138
Hong, S., Chen, N., Fang, W., Zhan, J., Liu, Q., Kang, S., He, X., Liu, L., Zhou, T., Huang, J., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1094598 · Cited by 138
Inflammation and cancer: tissue regeneration gone awry
Pesic, M. H., & Greten, F. R. (2016) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2016.07.010 · Cited by 137
Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer
Luen, S. J., Savas, P. S., Fox, S. B., Salgado, R., & Loi, S. (2017) · Pathology · doi:10.1016/j.pathol.2016.10.010 · Cited by 137
Wong, A. N. M., McArthur, G. A., Hofman, M. S., & Hicks, R. J. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3691-7 · Cited by 137
The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO
Mondanelli, G., Ugel, S., Grohmann, U., & Bronte, V. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.002 · Cited by 137
Clinical assessment of immune-related adverse events
Sosa, A. E., Cadena, E. L., Olivé, C. S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918764628 · Cited by 137
Dutta, S., Ganguly, A., Chatterjee, K., Spada, S., & Mukherjee, S. (2023) · Biology · doi:10.3390/biology12020218 · Cited by 137
Huang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136
Chemotherapy remains an essential element of personalized care for persons with lung cancers
Hellmann, M. D., Li, B., Chaft, J. E., & Kris, M. G. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw271 · Cited by 136
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
Ock, C.-Y., Hwang, J., Keam, B., Kim, S.-B., Shim, J., Jang, H.-J., Park, S., Sohn, B. H., Cha, M., Ajani, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01018-0 · Cited by 136
written on behalf of the AME Academic Lung Cancer Cooperation Group, Hu, Y., Zhang, Q., Li, H., Michot, J., Liu, H., Zhan, P., Lv, T., & Song, Y. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.12.10 · Cited by 136
Simvastatin Suppresses Proliferation and Migration in Non-small Cell Lung Cancer via Pyroptosis
Wang, F., Liu, W., Ning, J., Wang, J., Lang, Y., Jin, X., Zhu, K., Wang, X., Li, X., Yang, F., et al. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23542 · Cited by 136
Khozin, S., Miksad, R. A., Adami, J., Boyd, M. E., Brown, N. R., Gossai, A., Kaganman, I., Kuk, D., Rockland, J. M., Pazdur, R., et al. (2019) · Cancer · doi:10.1002/cncr.32383 · Cited by 136
Fan, Y., Zhao, J., Wang, Q., Huang, D., Li, X., Chen, J., Fang, Y., Duan, J., Zhou, C., Hu, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.002 · Cited by 135
BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer
Nguyen‐Ngoc, T., Bouchaab, H., Adjei, A. A., & Peters, S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000644 · Cited by 135
Metadata
- Authors
- Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén Frontera, O., Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C. T., Lestini, B., & Spigel, D. R.
- Affiliations
- City Of Hope National Medical Center (US)
- The Netherlands Cancer Institute (NL)
- University of Perugia (IT)
- Ruhrlandklinik (DE)
- Russian Cancer Research Center NN Blokhin (RU)
- Moffitt Cancer Center (US)
- University of Chicago (US)
- Oncology Hematology Care (US)
- Duke Medical Center (US)
- Massachusetts General Hospital (US)
- Fakultní nemocnice Bulovka (CZ)
- University Hospital Heidelberg (DE)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Amphia Ziekenhuis (NL)
- Hospital Universitario Virgen del Rocío (ES)
- LungenClinic Grosshansdorf (DE)
- Bristol-Myers Squibb (United States) (US)
- Tennessee Oncology (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-09
- Volume
- 373
- Issue
- 2
- Pages
- 123-135
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4681400
- OpenAlex
- W2156353875
- Cited by
- 8,447
- References
- 22
- Citations by year
- 2026: 204 · 2025: 332 · 2024: 525 · 2023: 627 · 2022: 718 · 2021: 928 · 2020: 1065 · 2019: 969 · 2018: 1066 · 2017: 1001 · 2016: 803 · 2015: 184
- FWCI
- 444.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- nivolumab, docetaxel, squamous cell non-small cell lung cancer, PD-1 inhibitors, immune checkpoint inhibitors, overall survival, progression-free survival, PD-L1 expression, treatment-related adverse events, second-line therapy, previously treated patients, response rate, treatment safety and efficacy comparison, immunotherapy versus chemotherapy
- MeSH terms
- Docetaxel, Nivolumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Immunoglobulin G, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Taxoids, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
